Response to alemtuzumab in FIP1L1/PDGFRA-negative hypereosinophilic myocarditis on serial cardiac magnetic resonance imaging.
Division of Cardiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.Journal of the American College of Cardiology (impact factor: 14.16). 01/2012; 59(4):430. DOI:10.1016/j.jacc.2011.06.078
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.